Lakefront Biotherapeutics (LKFT) Raw Materials (2021 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Raw Materials for 5 consecutive years, with $26.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Raw Materials fell 52.14% year-over-year to $26.2 million; the TTM figure through Dec 2025 stood at $26.2 million (down 52.14% YoY), while the FY2025 annual figure was $26.2 million, down 52.14% from the prior year.
• Raw Materials retreated to $26.2 million in Q4 2025 per LKFT's latest filing, from $54.7 million in the prior quarter.
• Across five years, Raw Materials topped out at $59.5 million in Q4 2023 and bottomed at $16.4 million in Q4 2021.
• Historically, Raw Materials has averaged $39.3 million across 5 years, with a median of $39.9 million in 2022.
• Annual changes were most pronounced in 2022 — Raw Materials soared 142.81% — and 2025, when it sank 52.14%.
• Lakefront Biotherapeutics' Raw Materials stood at $16.4 million in 2021, then jumped by 142.81% to $39.9 million in 2022, then soared by 49.16% to $59.5 million in 2023, then decreased by 8.0% to $54.7 million in 2024, then tumbled by 52.14% to $26.2 million in 2025.
• Business Quant data shows LKFT's Raw Materials at $26.2 million in Q4 2025, $54.7 million in Q4 2024, and $59.5 million in Q4 2023.